Myokardia Company Profile (NASDAQ:MYOK)

About Myokardia (NASDAQ:MYOK)

Myokardia logoMyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MYOK
  • CUSIP: N/A
  • Web: www.myokardia.com/
Capitalization:
  • Market Cap: $437.24 million
  • Outstanding Shares: 31,455,000
Average Prices:
  • 50 Day Moving Avg: $13.57
  • 200 Day Moving Avg: $13.04
  • 52 Week Range: $10.55 - $22.83
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.86
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $41.27 million
  • Price / Sales: 10.37
  • Book Value: $4.30 per share
  • Price / Book: 3.16
Profitability:
  • EBIDTA: ($15,460,000.00)
  • Net Margins: -205.28%
  • Return on Equity: -33.01%
  • Return on Assets: -24.01%
Debt:
  • Current Ratio: 4.68%
  • Quick Ratio: 4.68%
Misc:
  • Average Volume: 137,319 shs.
  • Beta: 6.02
  • Short Ratio: 8.98
 
Frequently Asked Questions for Myokardia (NASDAQ:MYOK)

What is Myokardia's stock symbol?

Myokardia trades on the NASDAQ under the ticker symbol "MYOK."

How were Myokardia's earnings last quarter?

Myokardia Inc (NASDAQ:MYOK) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.36) by $0.01. The firm earned $5.60 million during the quarter, compared to the consensus estimate of $7 million. Myokardia had a negative return on equity of 33.01% and a negative net margin of 205.28%. The firm's revenue for the quarter was up 55.6% on a year-over-year basis. View Myokardia's Earnings History.

Where is Myokardia's stock going? Where will Myokardia's stock price be in 2017?

4 brokerages have issued 1 year price targets for Myokardia's stock. Their predictions range from $24.00 to $32.00. On average, they anticipate Myokardia's share price to reach $28.00 in the next twelve months. View Analyst Ratings for Myokardia.

Who are some of Myokardia's key competitors?

Who are Myokardia's key executives?

Myokardia's management team includes the folowing people:

  • Tassos Anastasios Gianakakos, President, Chief Executive Officer, Director
  • June Lee M.D., Chief Operating Officer
  • Jake Bauer, Senior Vice President - Finance and Corporate Development
  • Joseph Lambing Ph.D., Senior Vice President - Nonclinical and Pharmaceutical Development
  • Robert Scott McDowell Ph.D., Senior Vice President - Drug Discovery
  • Marc Semigran M.D., Chief Medical Officer
  • Mark L. Perry J.D., Interim Non-Executive Chairman of the Board, Lead Independent Director
  • Kevin P. Starr, Director
  • Sunil Agarwal M.D., Independent Director
  • Mary B. Cranston, Independent Director

How do I buy Myokardia stock?

Shares of Myokardia can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myokardia's stock price today?

One share of Myokardia stock can currently be purchased for approximately $13.60.


MarketBeat Community Rating for Myokardia (NASDAQ MYOK)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about Myokardia and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Myokardia (NASDAQ:MYOK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.00 (105.88% upside)

Analysts' Ratings History for Myokardia (NASDAQ:MYOK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017BMO Capital MarketsReiterated RatingOutperform$32.00LowView Rating Details
3/13/2017WedbushReiterated RatingOutperform$24.00HighView Rating Details
11/8/2016Cowen and CompanyReiterated RatingBuy$28.00N/AView Rating Details
9/22/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
7/12/2016Credit Suisse Group AGReiterated RatingBuy$16.00 -> $20.00N/AView Rating Details
(Data available from 7/22/2015 forward)

Earnings

Earnings History for Myokardia (NASDAQ:MYOK)
Earnings by Quarter for Myokardia (NASDAQ:MYOK)
Earnings History by Quarter for Myokardia (NASDAQ MYOK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.36)($0.37)$7.00 million$5.60 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.18)$0.44$3.55 million$28.60 millionViewN/AView Earnings Details
11/7/2016Q316($0.07)($0.35)$4.83 million$3.55 millionViewN/AView Earnings Details
8/9/2016Q216($0.33)($0.37)$3.55 million$3.55 millionViewN/AView Earnings Details
5/12/2016Q1($0.53)($0.32)$3.55 million$3.55 millionViewN/AView Earnings Details
3/18/2016Q4($0.68)($0.48)$3.55 million$3.55 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Myokardia (NASDAQ:MYOK)
2017 EPS Consensus Estimate: ($1.50)
2018 EPS Consensus Estimate: ($1.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.29)($0.29)($0.29)
Q2 20171($0.39)($0.39)($0.39)
Q3 20171($0.40)($0.40)($0.40)
Q4 20171($0.42)($0.42)($0.42)
Q1 20181($0.39)($0.39)($0.39)
Q2 20181($0.40)($0.40)($0.40)
Q3 20181($0.41)($0.41)($0.41)
Q4 20181($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Myokardia (NASDAQ:MYOK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Myokardia (NASDAQ:MYOK)
Insider Ownership Percentage: 46.10%
Institutional Ownership Percentage: 47.72%
Insider Trades by Quarter for Myokardia (NASDAQ:MYOK)
Institutional Ownership by Quarter for Myokardia (NASDAQ:MYOK)
Insider Trades by Quarter for Myokardia (NASDAQ:MYOK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/20/2017Anastasios GianakakosCEOSell1,412$15.00$21,180.00View SEC Filing  
3/20/2017Jake BauerInsiderSell667$15.00$10,005.00View SEC Filing  
10/3/2016SanofiMajor ShareholderBuy450,000$15.00$6,750,000.00View SEC Filing  
11/3/2015Anastasios GianakakosCEOBuy1,350$10.00$13,500.00View SEC Filing  
11/3/2015Jonathan C FoxInsiderBuy3,000$10.00$30,000.00View SEC Filing  
11/3/2015Mark L PerryDirectorBuy5,000$10.00$50,000.00View SEC Filing  
11/3/2015SanofiMajor ShareholderBuy900,000$10.00$9,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Myokardia (NASDAQ:MYOK)
Latest Headlines for Myokardia (NASDAQ:MYOK)
Source:
DateHeadline
finance.yahoo.com logoMyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : July 21, 2017
finance.yahoo.com - July 22 at 6:45 AM
americanbankingnews.com logoMyoKardia, Inc. (NASDAQ:MYOK) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 18 at 6:56 PM
finance.yahoo.com logoETFs with exposure to MyoKardia, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 6:45 AM
finance.yahoo.com logoMyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : July 12, 2017
finance.yahoo.com - July 13 at 7:06 AM
finance.yahoo.com logoMyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : July 11, 2017
finance.yahoo.com - July 12 at 5:47 AM
americanbankingnews.com logoMyoKardia, Inc. (NASDAQ:MYOK) Upgraded at TheStreet
www.americanbankingnews.com - July 11 at 11:54 AM
finance.yahoo.com logoMyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : June 28, 2017
finance.yahoo.com - June 28 at 11:38 AM
americanbankingnews.com logoMyoKardia, Inc. (MYOK) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 23 at 5:08 PM
finance.yahoo.com logoETFs with exposure to MyoKardia, Inc. : June 15, 2017
finance.yahoo.com - June 16 at 7:57 AM
finance.yahoo.com logoMyoKardia, Inc. :MYOK-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 9 at 6:57 PM
finance.yahoo.com logoMyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : June 2, 2017
finance.yahoo.com - June 2 at 8:07 PM
americanbankingnews.com logoMyokardia Inc (MYOK) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 29 at 4:56 PM
americanbankingnews.com logoMyokardia Inc (MYOK) Downgraded by TheStreet to "D+"
www.americanbankingnews.com - May 23 at 5:34 PM
americanbankingnews.com logoMyokardia Inc (MYOK) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 14 at 9:12 AM
americanbankingnews.com logoMyokardia Inc Expected to Earn Q2 2017 Earnings of ($0.39) Per Share (MYOK)
www.americanbankingnews.com - May 12 at 10:24 AM
americanbankingnews.com logoMyokardia Inc (MYOK) Earns "Outperform" Rating from BMO Capital Markets
www.americanbankingnews.com - May 10 at 4:02 PM
finance.yahoo.com logoMyoKardia reports 1Q loss
finance.yahoo.com - May 10 at 12:12 PM
americanbankingnews.com logoMyokardia Inc (MYOK) Announces Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 9 at 9:22 PM
finance.yahoo.com logoInvestor Network: MyoKardia, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 6:21 PM
finance.yahoo.com logoMyoKardia Reports First Quarter 2017 Financial Results and Operational Progress
finance.yahoo.com - May 9 at 6:21 PM
americanbankingnews.com logoMyokardia (MYOK) Given Coverage Optimism Score of 0.14
www.americanbankingnews.com - May 8 at 11:44 PM
americanbankingnews.com logoMyokardia Inc (MYOK) Receives $25.00 Consensus Price Target from Brokerages
www.americanbankingnews.com - May 6 at 12:50 AM
americanbankingnews.com logoMyokardia (MYOK) Receives Daily Coverage Optimism Score of -0.09
www.americanbankingnews.com - May 3 at 9:49 AM
finance.yahoo.com logoMyoKardia to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017
finance.yahoo.com - May 2 at 7:24 PM
americanbankingnews.com logoMyokardia Inc (MYOK) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 2 at 4:24 PM
americanbankingnews.com logoMyokardia (MYOK) Getting Somewhat Positive News Coverage, Report Finds
www.americanbankingnews.com - April 28 at 12:25 AM
bizjournals.com logoHow a new biotech model looks to disrupt a fatal genetic disease
www.bizjournals.com - April 27 at 7:14 PM
finance.yahoo.com logoMyoKardia, Inc. – Value Analysis (NASDAQ:MYOK) : April 26, 2017
finance.yahoo.com - April 26 at 6:34 PM
finance.yahoo.com logoMyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : April 25, 2017
finance.yahoo.com - April 25 at 6:00 PM
americanbankingnews.com logoMyokardia (MYOK) Given Daily News Impact Rating of -0.22
www.americanbankingnews.com - April 23 at 11:02 AM
americanbankingnews.com logoShort Interest in Myokardia Inc (MYOK) Drops By 17.7%
www.americanbankingnews.com - April 20 at 5:56 PM
americanbankingnews.com logoMyokardia (MYOK) Getting Somewhat Favorable Press Coverage, Report Finds
www.americanbankingnews.com - April 19 at 12:59 PM
finance.yahoo.com logoMyoKardia Appoints David Meeker, M.D., to Board of Directors
finance.yahoo.com - April 18 at 10:14 AM
finance.yahoo.com logoETFs with exposure to MyoKardia, Inc. : April 13, 2017
finance.yahoo.com - April 13 at 6:27 PM
finance.yahoo.com logoMyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : April 6, 2017
finance.yahoo.com - April 7 at 11:24 AM
americanbankingnews.com logoMyokardia Inc (MYOK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 5 at 3:40 PM
americanbankingnews.com logoInsider Selling: Myokardia Inc (MYOK) Insider Sells 667 Shares of Stock
www.americanbankingnews.com - March 22 at 11:07 PM
americanbankingnews.com logoMyokardia Inc (MYOK) CEO Anastasios Gianakakos Sells 1,412 Shares
www.americanbankingnews.com - March 22 at 10:49 PM
reuters.com logoBRIEF-Myokardia appoints Kim Popovits, Wendy Yarno to board
www.reuters.com - March 18 at 9:09 AM
finance.yahoo.com logoMyoKardia Appoints Kim Popovits and Wendy Yarno to Board of Directors
finance.yahoo.com - March 17 at 8:38 AM
americanbankingnews.com logoMyokardia Inc (MYOK) to Post Q1 2017 Earnings of ($0.29) Per Share, Wedbush Forecasts
www.americanbankingnews.com - March 15 at 10:11 AM
reuters.com logoBRIEF-Myokardia Q4 net income $14.3 mln
www.reuters.com - March 13 at 6:26 PM
us.rd.yahoo.com logoMyoKardia Reports Fourth Quarter and Full Year 2016 Financial Results and Operational Progress
us.rd.yahoo.com - March 13 at 10:13 AM
sg.finance.yahoo.com logoMyoKardia reports 4Q loss
us.rd.yahoo.com - March 13 at 10:13 AM
biz.yahoo.com logoMYOKARDIA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - March 6 at 8:16 AM
thestreet.com logo7 Stocks Trending With Monster Volume
www.thestreet.com - March 2 at 9:20 AM
finance.yahoo.com logoMyoKardia to Present at Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - February 28 at 10:18 AM
reuters.com logoBRIEF-Myokardia says first subjects dosed in cardiomyopathy drug study
www.reuters.com - February 3 at 7:28 PM
finance.yahoo.com logoFirst Subjects Dosed in Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491
finance.yahoo.com - February 2 at 7:35 PM
streetinsider.com logoMyoKardia (MYOK) Appoints June Lee as COO
www.streetinsider.com - February 2 at 12:47 AM

Social

Chart

Myokardia (MYOK) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by MarketBeat.com Staff